Novo Nordisk loses global market lead to Eli Lilly outside the US
By
@finans.dk
More flour than flavour. There's a bagel in here, just not much of one.
Summary
Novo Nordisk, the Danish pharmaceutical giant, is losing its global market leadership to rival Eli Lilly, not just in the crucial US market but also internationally. New data reveals that Novo Nordisk has lost its historical lead and is losing market share outside the US to its archrival Eli Lilly. The article features commentary from analysts and top executives from both companies, highlighting cracks in Novo Nordisk's global growth strategy.
Key quotes
· 3 pulledNovo Nordisk presses nu på endnu en afgørende flanke.
Nye tal viser, at den danske medicinalgigant har mistet sit historiske forspring og taber terræn til Eli Lilly på markedsandele uden for USA.
Ærkerival buldrer frem: Analytiker afslører årsagen til Novos mistede forspring
You might also wanna read
Replimune to resubmit melanoma drug for FDA approval after agency leadership changes
Replimune plans to resubmit its melanoma drug for FDA approval following a leadership shakeup at the agency. The drug was twice rejected und
cnb.cx·2d ago
GLP-1 weight loss drugs reduce food spending, creating a $6.5 billion challenge for major grocery retailers
The article discusses how GLP-1 weight loss drugs like tirzepatide are significantly impacting consumer spending on food, creating a $6.5 bi
bit.ly·4d ago
Ebola Outbreak Spreads as Eli Lilly Invests $4 Billion in Vaccine Deals
This article covers multiple health and investment topics in a newsletter format. Key points include: the Ebola outbreak in the Democratic R
forbes.com·4d ago
Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t
theguardian.com·4mo ago
Interview with Sandoz CEO Richard Saynor on Generic Pharmaceuticals Industry
This article discusses an interview with Richard Saynor, head of Sandoz, focusing on the generic pharmaceuticals industry and its difference
science.org·7mo ago
Tylenol-maker's stock declines amid RFK Jr's reported plans to suggest autism link
Shares of Tylenol-maker Kenvue dropped after reports that RFK Jr will suggest a link between acetaminophen use during pregnancy and autism.
bbc.com·8mo ago